BCAX
insider transactionsBicara Therapeutics Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-78.9K
0 buy · 78.9K sell
Net value · 90d
-$1.7M
$0 in · $1.7M out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
10
0 buy · 78.9K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
Transactions · 90d
-
Grant·A
Director
$0
19.5K sh
Own New
-
Grant·A
Director
$0
19.5K sh
Own New
-
Grant·A
Director
$0
19.5K sh
Own New
-
Grant·A
Director
$0
19.5K sh
Own New
-
Grant·A
Director
$0
19.5K sh
Own New
-
Grant·A
Director
$0
19.5K sh
Own New
-
Grant·A
Director, 10% Owner
$0
19.5K sh
Own New
-
Exercise·M
Hyep Ivan KEY
Chief Financial Officer · 10b5-1
$0
9.2K sh
Own +15%
-
Sell·S
Hyep Ivan KEY
Chief Financial Officer · 10b5-1
$187.9K
9.2K sh · $20.42
Own -6%
-
Exercise·M
Hyep Ivan KEY
Chief Financial Officer · 10b5-1
$34.9K
9.2K sh · $3.79
Own +6%
-
Exercise·M
Mazumdar Claire KEY
Chief Executive Officer · 10b5-1
$0
15.0K sh
Own +11%
-
Sell·S
Mazumdar Claire KEY
Chief Executive Officer · 10b5-1
$300.6K
15.0K sh · $20.04 avg · 2 lots
Own -4%
-
Exercise·M
Mazumdar Claire KEY
Chief Executive Officer · 10b5-1
$56.8K
15.0K sh · $3.79
Own +4%
-
Exercise·M
Cohlhepp Ryan KEY
President and COO · 10b5-1
$0
8.0K sh
Own +9%
-
Sell·S
Cohlhepp Ryan KEY
President and COO · 10b5-1
$253.6K
12.5K sh · $20.29 avg · 2 lots
Own -6%
-
Exercise·M
Cohlhepp Ryan KEY
President and COO · 10b5-1
$30.3K
8.0K sh · $3.79
Own +4%
-
Grant·A
Chief Medical Officer
$0
85.0K sh
Own New
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
5.5K sh
Own +15%
-
Sell·S
Chief Medical Officer · 10b5-1
$125.8K
5.5K sh · $22.88
Own -9%
-
Exercise·M
Chief Medical Officer · 10b5-1
$20.8K
5.5K sh · $3.79
Own +10%
-
Exercise·M
Hyep Ivan KEY
Chief Financial Officer · 10b5-1
$0
9.2K sh
Own +30%
-
Sell·S
Hyep Ivan KEY
Chief Financial Officer · 10b5-1
$211.6K
9.2K sh · $23.00
Own -6%
-
Exercise·M
Hyep Ivan KEY
Chief Financial Officer · 10b5-1
$34.9K
9.2K sh · $3.79
Own +6%
-
Exercise·M
Mazumdar Claire KEY
Chief Executive Officer · 10b5-1
$0
37.8K sh · 4 lots
Own +31%
-
Sell·S
Mazumdar Claire KEY
Chief Executive Officer · 10b5-1
$354.1K
15.0K sh · $23.61
Own -4%
-
Exercise·M
Mazumdar Claire KEY
Chief Executive Officer · 10b5-1
$160.2K
37.8K sh · $4.24 avg · 4 lots
Own +11%
-
Exercise·M
Cohlhepp Ryan KEY
President and COO · 10b5-1
$0
8.0K sh
Own +8%
-
Sell·S
Cohlhepp Ryan KEY
President and COO · 10b5-1
$287.6K
12.5K sh · $23.01 avg · 2 lots
Own -6%
-
Exercise·M
Cohlhepp Ryan KEY
President and COO · 10b5-1
$30.3K
8.0K sh · $3.79
Own +4%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 9, 2026 | Bowden Christopher | Grant A | 19.5K | $0 |
| Jun 9, 2026 | Haviland Kate | Grant A | 19.5K | $0 |
| Jun 9, 2026 | Mazumdar-Shaw Kiran | Grant A | 19.5K | $0 |
| Jun 9, 2026 | Robertson Scott M. | Grant A | 19.5K | $0 |
| Jun 9, 2026 | POWELL MICHAEL | Grant A | 19.5K | $0 |
| Jun 9, 2026 | Simson Jake | Grant A | 19.5K | $0 |
| Jun 9, 2026 | RA CAPITAL MANAGEMENT, L.P. | Grant A | 19.5K | $0 |
| May 21, 2026 | Hyep Ivan KEY 10b5-1 | Exercise M | 9.2K | $0 |
| May 21, 2026 | Hyep Ivan KEY 10b5-1 | Sell S | 9.2K | $187.9K |
| May 21, 2026 | Hyep Ivan KEY 10b5-1 | Exercise M | 9.2K | $34.9K |
| May 18, 2026 | Mazumdar Claire KEY 10b5-1 | Exercise M | 15.0K | $0 |
| May 18, 2026 | Mazumdar Claire KEY 10b5-1 | Sell S | 15.0K2 lots | $300.6K |
| May 18, 2026 | Mazumdar Claire KEY 10b5-1 | Exercise M | 15.0K | $56.8K |
| May 15, 2026 | Cohlhepp Ryan KEY 10b5-1 | Exercise M | 8.0K | $0 |
| May 15, 2026 | Cohlhepp Ryan KEY 10b5-1 | Sell S | 12.5K2 lots | $253.6K |
| May 15, 2026 | Cohlhepp Ryan KEY 10b5-1 | Exercise M | 8.0K | $30.3K |
| May 8, 2026 | William Schelman | Grant A | 85.0K | $0 |
| Apr 27, 2026 | Raben David 10b5-1 | Exercise M | 5.5K | $0 |
| Apr 27, 2026 | Raben David 10b5-1 | Sell S | 5.5K | $125.8K |
| Apr 27, 2026 | Raben David 10b5-1 | Exercise M | 5.5K | $20.8K |
| Apr 21, 2026 | Hyep Ivan KEY 10b5-1 | Exercise M | 9.2K | $0 |
| Apr 21, 2026 | Hyep Ivan KEY 10b5-1 | Sell S | 9.2K | $211.6K |
| Apr 21, 2026 | Hyep Ivan KEY 10b5-1 | Exercise M | 9.2K | $34.9K |
| Apr 20, 2026 | Mazumdar Claire KEY 10b5-1 | Exercise M | 37.8K4 lots | $0 |
| Apr 20, 2026 | Mazumdar Claire KEY 10b5-1 | Sell S | 15.0K | $354.1K |
| Apr 20, 2026 | Mazumdar Claire KEY 10b5-1 | Exercise M | 37.8K4 lots | $160.2K |
| Apr 15, 2026 | Cohlhepp Ryan KEY 10b5-1 | Exercise M | 8.0K | $0 |
| Apr 15, 2026 | Cohlhepp Ryan KEY 10b5-1 | Sell S | 12.5K2 lots | $287.6K |
| Apr 15, 2026 | Cohlhepp Ryan KEY 10b5-1 | Exercise M | 8.0K | $30.3K |
Buy Sell Non-market (grant · exercise · gift)
About BCAX insider trading
This page tracks insider transactions for Bicara Therapeutics Inc. (BCAX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.